Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B-cell lymphoma
Lenalidomide has moderate activity in relapsed or refractory diffuse large B-cell lymphoma. Its efficacy may be improved by combination with chemotherapy.